Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...
In a recent editorial published in Current Pharmaceutical Analysis (Volume 18, Issue 6, 2022), researchers Dr. Behrouz Seyfinejad and Dr. Abolghasem Jouyban highlight the importance of method ...
Precision medicine is driven by advances in omics technologies that facilitate identification of mutations and the presence or absence of certain molecular targets, which, in turn, enables streamlined ...
Traditional approaches for detecting Alzheimer’s disease (AD) that rely on examining the brain for amyloid plaques have limitations in accuracy and early detection. Although the industry has ...
An oft-heard complaint in R&D is that technology can’t keep up with the concepts that scientists are trying to prove or disprove. “In the case of biomarkers, having the technology is simply not the ...
Immunohistochemical analysis of the tumor microenvironment in acral lentiginous melanoma (ALM). Immunoprint IHC test detects high-risk stage IB/IIA patients.
Spatial analysis of protein or gene expression is vital to understanding the distribution, phenotypes, and interactions between cells within tumor microenvironment (TME). Traditionally, multiplexed ...
FRANKFURT, Germany--(BUSINESS WIRE)--NeraCare, a leading developer of laboratory tests for personalized survival prediction of melanoma patients, today announced publication of an abstract describing ...
A range of new non-serum biomarkers have been identified in recent years, but the authors of a new review urge caution until those markers are further validated. A number of recent reports have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results